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Transplant (n¼16) Chemotherapy (n¼25)
Age, median (range) 42 (19-66) 52 (9-82)
Sex
Male 9 17
Female 7 8
Immunophenotypic Subtypes
B/My 11 10
T/My 4 14
B/T 1 1
Cytogenetic
Diploid 3 7
Complex 6 9
Ph+ 1 3
MLL 2 0
Others 4 6
Induction
Lymphoid 7 13
Myeloid 3 2
Hybrid 6 10
Response
Complete
Remission
12 15
No Response 4 10
Status at Transplant
First Complete
Remission
9 -
Primary Induction
Failure
4 -
Active disease 3 -
Transplant Regimen
Myeloablative 10 -
Reduced Intensity 6 -
Donor
Matched Related 6 -
Matched Unrelated 8 -
Mismatched 2 -
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Sixteen patients received hematopoietic stem cell trans-
plantation (HSCT) in ﬁrst remission (n¼9) or with active
disease (n¼7) following a myeloablative (n¼10) or reduced
intensity (n¼6) conditioning regimen. The median survival
from the time of diagnosis was 19 months (range, 1 e 82
months). On univariate analysis, complete response to
induction therapy was a signiﬁcant predictor of survival (65%
vs. 9%, P < .001). Additionally, there was a trend toward
better overall survival for patients who received HSCT
compared with the patients who were treated with chemo-
therapy alone (60% versus 35%, P ¼ .083). Differences in
immunophenotypic subtypes or karyotype did not impact
the overall survival.
Patients with MPAL represent a rare and heterogeneous
category of leukemia with poor prognosis. The stricter clas-
siﬁcation schema should help to lessen heterogeneity and
allow for better understanding of the leukemia, and ulti-
mately better patient outcomes. Our small series suggests
that response to induction portends better survival.
Furthermore, hematopoietic stem cell transplantation can
further improve outcomes.226
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Background: The current acceptable conditioning regimen
used for hematopoietic stem cell transplantation (HSCT) in
pediatric leukemia consists of total body irradiation (TBI)
especially in acute lymphoblastic leukemia (ALL). Consid-
ering the complications and limitations of TBI-based condi-
tioning regimens, some studies tried to uses non-TBI
conditioning regimens.
Methods: From 1992 to 2012 in a retrospective study from
our center pediatric patients (age <15) with acute myelo-
balstic leukemia (AML) and ALL candidate for HSCT included.
The patients were prepared using a non-radiation-based
conditioning regimen (busulfan/cyclophosphamide in allo-
genic and busulfan/etoposide in autologus). In the allogenic
HSCT, Cyclosporine A and methotrexate were used as graft-
versus-host disease (GvHD) prophylaxis regimen.
Results: Of 268 patients with AML (autologus¼57,
allogenic¼104) and ALL (allogenic¼107), 137(51%) of them
were boys and 131(49%) were girls. The median age at
transplantation were 11years (range: 1-15years) in AML
patients and 12years (range: 0.8-15years) in ALL patients.
With a median follow up of 31 months for AML patients,
overall survival (OS), disease free survival (DFS) for autologus
and allogenic transplantations were 64%, 59.2% and 69%,
61.5% respectively. In ALL patients with a median follow up of
14 months, OS and DFS were 80.3% and 70%. The most
common cause of deaths in both AML and ALL patients was
relapse (63% and 71%). Regarding GVHD occurrence, in AML
and ALL patients 67 (41.6%) and 61 (57%) did experience
acute GVHD. Considering chronic GVHD for AML and ALL
patients, results were 20(12.4%) and 13(12.1%).
Conclusion: Regarding the adverse effects of using TBI-
based conditioning regimen, it seems that in pediatric
patients with AML and ALL using a non-TBI based condi-
tioning regimen can be a good alternative in HSCT. However,
large controlled well-designed studies are needed for further
understanding of differences between TBI and non-TBI
conditioning regimens.227
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Introduction: Optimal sampling interval, sample source and
technique to detect impending relapse after hematopoietic
cell transplantation (HCT) is not well-deﬁned. For most
myeloid malignancies (except CML) donor chimerisms,
peripheral blood parameters, and bone marrow cytomor-
phology are the main options for disease detection post-HCT.
The role of molecular markers is still evolving. The aim of our
study is to evaluate the usefulness of 3 monthly bone
marrow (BM) evaluations for the ﬁrst year after HCT using
these techniques in predicting relapse.
